Suppr超能文献

细胞间信号通路作为血管性痴呆修复的治疗靶点

Intercellular Signaling Pathways as Therapeutic Targets for Vascular Dementia Repair.

作者信息

Tian Min, Kawaguchi Riki, Shen Yang, Machnicki Michal, Villegas Nikole G, Cooper Delaney R, Montgomery Natalia, Haring Jacqueline, Lan Ruirui, Yuan Angelina H, Williams Christopher K, Magaki Shino, Vinters Harry V, Zhang Ye, De Biase Lindsay M, Silva Alcino J, Carmichael S Thomas

出版信息

bioRxiv. 2024 Mar 27:2024.03.24.585301. doi: 10.1101/2024.03.24.585301.

Abstract

Vascular dementia (VaD) is a white matter ischemic disease and the second-leading cause of dementia, with no direct therapy. Within the lesion site, cell-cell interactions dictate the trajectory towards disease progression or repair. To elucidate the underlying intercellular signaling pathways, a VaD mouse model was developed for transcriptomic and functional studies. The mouse VaD transcriptome was integrated with a human VaD snRNA-Seq dataset. A custom-made database encompassing 4053 human and 2032 mouse ligand-receptor (L-R) interactions identified significantly altered pathways shared between human and mouse VaD. Two intercellular L-R systems, Serpine2-Lrp1 and CD39-A3AR, were selected for mechanistic study as both the ligand and receptor were dysregulated in VaD. Decreased Seprine2 expression enhances OPC differentiation in VaD repair. A clinically relevant drug that reverses the loss of CD39-A3AR function promotes tissue and behavioral recovery in the VaD model. This study presents novel intercellular signaling targets and may open new avenues for VaD therapies.

摘要

血管性痴呆(VaD)是一种白质缺血性疾病,是导致痴呆的第二大原因,目前尚无直接的治疗方法。在病变部位,细胞间相互作用决定了疾病进展或修复的轨迹。为了阐明潜在的细胞间信号通路,开发了一种VaD小鼠模型用于转录组学和功能研究。将小鼠VaD转录组与人类VaD单细胞核RNA测序(snRNA-Seq)数据集进行整合。一个包含4053个人类和2032个小鼠配体-受体(L-R)相互作用的定制数据库,确定了人类和小鼠VaD之间共享的显著改变的信号通路。选择两个细胞间L-R系统,即丝氨酸蛋白酶抑制剂2(Serpine2)-低密度脂蛋白受体相关蛋白1(Lrp1)和CD39-腺苷A3受体(A3AR)进行机制研究,因为在VaD中配体和受体均失调。Serpine2表达降低增强了VaD修复过程中少突胶质前体细胞(OPC)的分化。一种可逆转CD39-A3AR功能丧失的临床相关药物可促进VaD模型中的组织和行为恢复。本研究提出了新的细胞间信号靶点,可能为VaD治疗开辟新途径。

相似文献

1
Intercellular Signaling Pathways as Therapeutic Targets for Vascular Dementia Repair.
bioRxiv. 2024 Mar 27:2024.03.24.585301. doi: 10.1101/2024.03.24.585301.
4
Novel pathophysiological markers are revealed by iTRAQ-based quantitative clinical proteomics approach in vascular dementia.
J Proteomics. 2014 Mar 17;99(100):54-67. doi: 10.1016/j.jprot.2014.01.011. Epub 2014 Jan 19.
5
Bile acid synthesis, modulation, and dementia: A metabolomic, transcriptomic, and pharmacoepidemiologic study.
PLoS Med. 2021 May 27;18(5):e1003615. doi: 10.1371/journal.pmed.1003615. eCollection 2021 May.
6
Vascular dementia today.
Rev Neurol (Paris). 1999;155 Suppl 4:S64-72.
7
Vascular dementia may be the most common form of dementia in the elderly.
J Neurol Sci. 2002 Nov 15;203-204:7-10. doi: 10.1016/s0022-510x(02)00252-6.
9
Diagnosis and management of vascular cognitive impairment and dementia.
J Neural Transm Suppl. 2002(63):91-109. doi: 10.1007/978-3-7091-6137-1_6.
10
Metabolic profiling deciphering the potential targets of Yi-Gan San against vascular dementia in rat.
Brain Res. 2020 Jan 15;1727:146512. doi: 10.1016/j.brainres.2019.146512. Epub 2019 Nov 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验